Brought to you by 
Bluebird bio nets $477.5mm through public stock sale
24 Jun 2015
Executive Summary
Gene therapeutics developer bluebird bio Inc. netted $477.5mm by publicly selling 2.9mm common shares at $170. (The price per share is double what the firm sold shares for in its last public offering about six months ago.) Proceeds will help bluebird advance its immuno-oncology R&D efforts (including IND filing and Phase I trials of an anti-BCMA compound for multiple myeloma), and will also go towards building a European infrastructure, expanding manufacturing capabilities, and upcoming trials of LentiGlobin in the US and Europe for beta-thalassemia major.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bluebird bio nets $477.5mm through public stock sale
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice